At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ELDN Eledon Pharmaceuticals, Inc.
Post-Market Trading 12-20 19:01:05 EST
4.36
+0.14
+3.32%
盘后4.36
+0.000.00%
16:02 EST
High4.42
Low3.95
Vol2.23M
Open4.20
D1 Closing4.22
Amplitude11.14%
Mkt Cap260.46M
Tradable Cap201.83M
Total Shares59.74M
T/O9.65M
T/O Rate4.82%
Tradable Shares46.29M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Eledon Pharmaceuticals Price Target Maintained With a $16.00/Share by HC Wainwright & Co.
BRIEF-Eledon Pharmaceuticals Announces Positive Initial Data From Subjects With Type 1 Diabetes Treated With Tegoprubart As Part Of An Immunosuppression Regimen Following Islet Transplantation In Investigator-Initiated Trial At Uchicago Medicine
Eledon Pharmaceuticals Announces Positive Initial Data From Subjects With Type 1 Diabetes Treated With Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at Uchicago Medicine
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine
Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.